1. 2 The paper deals largely with conflicting interests rather than “conflicts of interest.” Although some of the discussion concerns conflicting interests that give rise to conflicts of interest, full discussion of such conflicts of interest awaits another paper.
2. 4 See, for example, Ortho Pharmaceutical Corp. v. Amgen, Inc., 882 F.2d 806 (3d Cir. 1989); and Re Joint Ventures Between Baxter International Inc. and Nestle SA, [1992] 5 C.M.L.R. M33.
3. “Benefit vs. Risk: How FDA Approves New Drugs,”;Farley;FDA Consumer,1987
4. “Nucleosides. V. The Monomesylates of 1-(2′-Deoxy-beta-lyrofuranosyl)thymine,”;Horwitz;Journal of Organic Chemistry,1964
5. 6 Pub. L. No. 96–517 (1980) (codified at 35 U.S.C. § 200, et seq. (1994)). The act was amended in 1984 to extend its coverage to national laboratories operated by universities or nonprofit organizations. Pub. L. No. 98–620 (1984).